Cyclosporin safety in a simplified rat brain tumor implantation model

• Autor(a) principal: Felix,Francisco H. C.
• Data de Publicação: 2012
• Outros Autores: Fontenele,Juvenia B., Teles,Milena G., Bezerra Neto,João E., Santiago,Márcia H. A. M., Picanço Filho,Roberto L., Menezes,Dalgimar B. de, Viana,Glauce S. B., Moraes,Manoel O. de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de neuro-psiquiatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2012000100011
• topic: brain neoplasms; neoplasms; experimental; carcinoma 256; Walker; cachexia; cell movement; immunosuppressive agents

Brain cancer is the second neurological cause of death. A simplified animal brain tumor model using W256 (carcinoma 256, Walker) cell line was developed to permit the testing of novel treatment modalities. Wistar rats had a cell tumor solution inoculated stereotactically in the basal ganglia (right subfrontal caudate). This model yielded tumor growth in 95% of the animals, and showed absence of extracranial metastasis and systemic infection. Survival median was 10 days. Estimated tumor volume was 17.08±6.7 mm³ on the 7th day and 67.25±19.8 mm³ on 9th day post-inoculation. Doubling time was 24.25 h. Tumor growth induced cachexia, but no hematological or biochemical alterations. This model behaved as an undifferentiated tumor and can be promising for studying tumor cell migration in the central nervous system. Dexamethasone 3.0 mg/kg/day diminished significantly survival in this model. Cyclosporine 10 mg/kg/day administration was safely tolerated.